<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>QUALAQUIN - quinine sulfate capsule </strong><br>STAT RX USA LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use QUALAQUIN<span class="Sup">®</span> safely and effectively. See full prescribing information for QUALAQUIN<span class="Sup">®</span>.<br> <br>QUALAQUIN<span class="Sup">®</span> (quinine sulfate) Capsules, USP for Oral use<br>Initial U.S. Approval: 2005<br> <br>BOXED WARNING (See full prescribing information for complete boxed warning)</div>
<div class="Warning"><div>
<h1 class="Warning">
								 
								</h1>
<h1 class="Warning"><span class="Bold"></span></h1>
<p class="Highlighta"><span class="Bold">WARNING:</span><br> <br><span class="Bold">QUALAQUIN<span class="Sup">®</span> use for the treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> may result in serious and life-threatening hematologic reactions, including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (HUS/TTP). <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic renal impairment</span> associated with the development of TTP has been reported. The risk associated with QUALAQUIN use in the absence of evidence of its effectiveness in the treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> outweighs any potential benefit (see <a href="#S5">WARNINGS</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="ib40d3b2d-9bae-46cd-8b49-0ad362f255ae"></a><table width="70%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><a href="#BOX">Boxed Warning</a></td>
<td align="right">11/2009</td>
</tr>
<tr>
<td align="left">Warnings and Precautions</td>
<td align="right"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (<a href="#S5.2">5.2</a>)</td>
<td align="right">11/2009</td>
</tr>
<tr>
<td align="left">Drug Interactions</td>
<td align="right"></td>
</tr>
<tr class="Botrule Last">
<td align="left">  Effects of Drugs on Quinine Pharmacokinetics (<a href="#S7.1">7.1</a>)</td>
<td align="right">11/2009</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
								 
								</h1>
<h1 class="Warning"><span class="Bold"></span></h1>
<p class="Highlighta"><span class="Bold">WARNING:</span><br> <br><span class="Bold">QUALAQUIN<span class="Sup">®</span> use for the treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> may result in serious and life-threatening hematologic reactions, including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (HUS/TTP). <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic renal impairment</span> associated with the development of TTP has been reported. The risk associated with QUALAQUIN use in the absence of evidence of its effectiveness in the treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> outweighs any potential benefit (see <a href="#S5">WARNINGS</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">QUALAQUIN<span class="Sup">®</span> (quinine sulfate) is a cinchona alkaloid indicated for treatment of uncomplicated <span class="Italics">Plasmodium falciparum </span><span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> (<a href="#S1">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adults (≥ 16 years of age):  648 mg (two capsules) every 8 hours for 7 days (<a href="#S2.1">2.1</a>).</li>
<li>Patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span>: one loading dose of 648 mg (two capsules) followed 12 hours later by 324 mg (one capsule) every 12 hours for 7 days (<a href="#S2.2">2.2</a>).</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>324 mg hard gelatin, clear cap/clear body capsules, imprinted with 'AR 102' (<a href="#S3">3</a>).</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">QUALAQUIN is contraindicated in patients with the following: </p>
<ul>
<li>Prolongation of QT interval (<a href="#S4">4</a>)</li>
<li>Glucose-6-phosphate dehydrogenase (G6PD) deficiency (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span> (<a href="#S4">4</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to quinine, mefloquine, or quinidine (<a href="#S4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span> (<a href="#S4">4</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Not indicated for the prevention or treatment of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>. Risk of serious and life-threatening adverse reactions (<a href="#S1">1</a>, <a href="#S5.1">5.1</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, including ITP and HUS/TTP, has been reported. Discontinue drug (<a href="#S5.2">5.2</a>).</li>
<li>QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Avoid concomitant use with drugs known to prolong QT interval (<a href="#S5.3">5.3</a>).</li>
<li>Avoid concomitant use with rifampin. QUALAQUIN treatment failures have been reported (<a href="#S5.4">5.4</a>).</li>
<li>Avoid concomitant use with neuromuscular blocking agents. QUALAQUIN may potentiate <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> and cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (<a href="#S5.5">5.5</a>).</li>
<li>Serious and life threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Discontinue drug (<a href="#S4">4</a>, <a href="#S5.6">5.6</a>). </li>
<li><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> and flutter. Paradoxical increase in ventricular rate may occur. Closely monitor digoxin levels if used concomitantly (<a href="#S5.7">5.7</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>. Monitor for signs and symptoms (<a href="#S5.8">5.8</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are a cluster of symptoms called "<span class="product-label-link" type="condition" conceptid="4292266" conceptname="Cinchonism">cinchonism</span>", which occurs to some degree in almost all patients taking quinine:  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, vasodilation and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, hearing impairment, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, disturbance in color perception, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, and disturbances in cardiac rhythm or conduction (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mutual Pharmaceutical Company, Inc. at 1-888-351-3786 or drugsafety@urlpharma.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<span class="Italics">.</span></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<a name="ifc3bae65-f73e-4d8e-887a-7d7fb6bb2199"></a><table width="80%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Interacting Drug</th>
<th class="Rrule" align="left">Interaction</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Drugs known to prolong QT interval (e.g., Class IA and Class III antiarrhythmic agents).</td>
<td class="Rrule" align="left">QUALAQUIN prolongs QT interval, ECG abnormalities including QT prolongation and Torsades des Pointes. Avoid concomitant use (<a href="#S5.3">5.3</a>).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Other antimalarials (e.g., halofantrine, mefloquine).</td>
<td class="Rrule" align="left">ECG abnormalities including QT prolongation. Avoid concomitant use (<a href="#S5.3">5.3</a>, <a href="#S7.2">7.2</a>).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CYP3A4 inducers or inhibitors</td>
<td class="Rrule" align="left">Alteration in plasma quinine concentration. Monitor for lack of efficacy or increased adverse events of quinine (<a href="#S7.1">7.1</a>).</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CYP3A4 and CYP2D6 substrates</td>
<td class="Rrule" align="left">Quinine is an inhibitor of CYP3A4 and CYP2D6. Monitor for lack of efficacy or increased adverse events of the co-administered drug (<a href="#S7.1">7.1</a>).</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Digoxin</td>
<td class="Rrule" align="left">Increased digoxin plasma concentration (<a href="#S5.8">5.8</a>, <a href="#S7.1">7.1</a>).</td>
</tr>
</tbody>
</table>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Reduce dose and dosing frequency for patients with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> (<a href="#S2.2">2.2</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: Closely monitor for adverse events (<a href="#S8.7">8.7</a>, <a href="#S12.3">12.3</a>).</li>
<li>Pregnancy: Based on animal data may cause fetal harm. Use only if the potential benefit justifies the risk (<a href="#S8.1">8.1</a>).</li>
<li>Nursing Mothers: Exercise caution when administering to a nursing woman (<a href="#S8.3">8.3</a>).</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 11/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING:</span></a></h1>
<h1><a href="#section-1" class="toc">1       INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2       DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1    Treatment of Uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3       DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4       CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5       WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1    Use of QUALAQUIN for Treatment or Prevention of Nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg Cramps</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2     <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3     QT Prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4     Concomitant Use of Rifampin</a></h2>
<h2><a href="#section-5.5" class="toc">5.5     Concomitant Use of Neuromuscular Blocking Agents</a></h2>
<h2><a href="#section-5.6" class="toc">5.6     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7     <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> and Flutter</a></h2>
<h2><a href="#section-5.8" class="toc">5.8     <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h1><a href="#section-6" class="toc">6       ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1     Overall</a></h2>
<h1><a href="#section-7" class="toc">7      DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1   Effects of Drugs and Other Substances on Quinine Pharmacokinetics</a></h2>
<h2><a href="#section-7.2" class="toc">7.2     Effects of Quinine on the Pharmacokinetics of Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3     Drug/Laboratory Interactions</a></h2>
<h1><a href="#section-8" class="toc">8       USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2     Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3     Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4     Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5     Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10      OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11      DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12      CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1   Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2   Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3   Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4   Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13      NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14      CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16       HOW SUPPLIED / STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1    How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2   Storage</a></h2>
<h1><a href="#section-15" class="toc">17       PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1   Dosing Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING:</span></h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">QUALAQUIN<span class="Sup">®</span> use for the treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> may result in serious and life-threatening hematologic reactions, including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (HUS/TTP). <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic renal impairment</span> associated with the development of TTP has been reported. The risk associated with QUALAQUIN use in the absence of evidence of its effectiveness in the treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> outweighs any potential benefit (see <a href="#S5">WARNINGS</a>).</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1       INDICATIONS AND USAGE</h1>
<p class="First">QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated <span class="Italics">Plasmodium falciparum </span><span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [<span class="Italics">see <a href="#S14">Clinical Studies (14)</a></span>].</p>
<p>QUALAQUIN oral capsules are not approved for:</p>
<ul>
<li>Treatment of severe or complicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</li>
<li>Treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2       DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1    Treatment of Uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></h2>
<p class="First">For treatment of uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in adults:  Orally, 648 mg (two capsules) every 8 hours for 7 days [<span class="Italics">see <a href="#S14">Clinical Studies (14)</a></span>].</p>
<p>QUALAQUIN should be taken with food to minimize gastric upset [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with acute uncomplicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> and severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span>, the following dosage regimen is recommended: one loading dose of 648 mg QUALAQUIN followed 12 hours later by maintenance doses of 324 mg every 12 hours. </p>
<p>The effects of mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the safety and pharmacokinetics of quinine sulfate are not known [<span class="Italics">see <a href="#S8.6">Use in Specific Populations (8.6)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3       DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">324 mg capsules - hard gelatin, clear cap/clear body, imprinted with 'AR 102'</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4       CONTRAINDICATIONS</h1>
<p class="First">QUALAQUIN is contraindicated in patients with the following:</p>
<ul>
<li>Prolonged QT interval. One case of a fatal <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> was reported in an elderly patient with a prolonged QT interval at baseline, who received quinine sulfate intravenously for <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>]<span class="Italics">.</span>
</li>
<li>Glucose-6-phosphate dehydrogenase (G6PD) deficiency.</li>
<li><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> can occur in patients with G6PD deficiency receiving quinine.</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to quinine.<ul class="Disc"><li>These include, but are not limited to, the following [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>]:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenia</span> purpura (ITP) and <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> (TTP)</li>
<li><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span> (HUS)</li>
<li><span class="product-label-link" type="condition" conceptid="437216" conceptname="Black water fever">Blackwater fever</span> (acute <span class="product-label-link" type="condition" conceptid="4049138" conceptname="Intravascular hemolysis">intravascular hemolysis</span>, <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span>, and <span class="product-label-link" type="condition" conceptid="4049428" conceptname="Hemoglobinemia">hemoglobinemia</span>)</li>
</ul>
</li></ul>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mefloquine or quinidine: cross-sensitivity to quinine has been documented [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>]<span class="Italics">.</span><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span>. Quinine has neuromuscular blocking activity, and may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span>. Quinine may exacerbate active <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> [<span class="Italics">see <a href="#S6">Adverse Reactions (6)</a></span>].</li>
</ul>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5       WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1    Use of QUALAQUIN for Treatment or Prevention of Nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg Cramps</span></h2>
<p class="First">QUALAQUIN may cause unpredictable serious and life-threatening hematologic reactions including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and hemolytic-<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremic syndrome</span>/<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (HUS/TTP) in addition to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, QT prolongation, serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other serious adverse events requiring medical intervention and hospitalization. <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic renal impairment</span> associated with the development of TTP, and fatalities have also been reported. The risk associated with the use of QUALAQUIN in the absence of evidence of its effectiveness for treatment or prevention of nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, outweighs any potential benefit in treating and/or preventing this benign, self-limiting condition [s<span class="Italics">ee <a href="#BOX">Boxed Warning </a></span>and <span class="Italics"><a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2     <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Quinine-induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> is an immune-mediated disorder. Severe cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that are fatal or life threatening have been reported, including cases of HUS/TTP. <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">Chronic renal impairment</span> associated with the development of TTP has also been reported. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> usually resolves within a week upon discontinuation of quinine. If quinine is not stopped, a patient is at risk for fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Upon re-exposure to quinine from any source, a patient with quinine-dependent antibodies could develop <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that is more rapid in onset and more severe than the original episode.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3     QT Prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span> </h2>
<p class="First">QT interval prolongation has been a consistent finding in studies which evaluated electrocardiographic changes with oral or parenteral quinine administration, regardless of age, clinical status, or severity of disease. The maximum increase in QT interval has been shown to correspond with peak quinine plasma concentration [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>]. Quinine sulfate has been rarely associated with potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>.</p>
<p>QUALAQUIN is not recommended for use with other drugs known to cause QT prolongation, including Class IA antiarrhythmic agents (e.g., quinidine, procainamide, disopyramide), and Class III antiarrhythmic agents (e.g., amiodarone, sotalol, dofetilide).</p>
<p>The use of macrolide antibiotics such as erythromycin should be avoided in patients receiving QUALAQUIN. Fatal <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> was reported in an elderly patient who received concomitant quinine, erythromycin, and dopamine. Although a causal relationship between a specific drug and the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> was not established in this case, erythromycin is a CYP3A4 inhibitor and could potentially increase quinine plasma levels when used concomitantly. A related macrolide antibiotic, troleandomycin, has been shown to increase quinine exposure in a pharmacokinetic study [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1)</a></span>].</p>
<p>Quinine may inhibit the metabolism of certain drugs that are CYP3A4 substrates and are known to cause QT prolongation, e.g., astemizole, cisapride, terfenadine, pimozide, halofantrine and quinidine. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsades de pointes</span> has been reported in patients who received concomitant quinine and astemizole. Therefore, concurrent use of QUALAQUIN with these medications, or drugs with similar properties, should be avoided [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2)</a></span>].</p>
<p>Concomitant administration of QUALAQUIN with the antimalarial drugs, mefloquine or halofantrine, may result in electrocardiographic abnormalities, including QT prolongation, and increase the risk for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> or other serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Concurrent use of QUALAQUIN and mefloquine may also increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2)</a></span>].</p>
<p>QUALAQUIN should also be avoided in patients with known prolongation of QT interval and in patients with clinical conditions known to prolong the QT interval, such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and certain cardiac conditions [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4     Concomitant Use of Rifampin</h2>
<p class="First">Treatment failures may result from the concurrent use of rifampin with QUALAQUIN, due to decreased plasma concentrations of quinine, and concomitant use of these medications should be avoided [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5     Concomitant Use of Neuromuscular Blocking Agents</h2>
<p class="First">The use of neuromuscular blocking agents should be avoided in patients receiving QUALAQUIN. In one patient who received pancuronium during an operative procedure, subsequent administration of quinine resulted in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Although there are no clinical reports with succinylcholine or tubocurarine, quinine may also potentiate <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> when used with these drugs [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> reported with quinine sulfate include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. </p>
<p>A number of other serious adverse reactions reported with quinine, including <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span> (TTP) and <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (HUS), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, immune <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> (ITP), <span class="product-label-link" type="condition" conceptid="437216" conceptname="Black water fever">blackwater fever</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, granulomatous <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span> may also be due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
<p>QUALAQUIN should be discontinued in case of any signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7     <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> and Flutter</h2>
<p class="First">QUALAQUIN should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> or <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>. A paradoxical increase in ventricular response rate may occur with quinine, similar to that observed with quinidine. If digoxin is used to prevent a rapid ventricular response, serum digoxin levels should be closely monitored, because digoxin levels may be increased with use of quinine [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8     <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Quinine stimulates release of insulin from the pancreas, and patients, especially pregnant women, may experience clinically significant <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6       ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1     Overall</h2>
<p class="First">Quinine can adversely affect almost every body system. The most common adverse events associated with quinine use are a cluster of symptoms called "<span class="product-label-link" type="condition" conceptid="4292266" conceptname="Cinchonism">cinchonism</span>", which occurs to some degree in almost all patients taking quinine. Symptoms of mild <span class="product-label-link" type="condition" conceptid="4292266" conceptname="Cinchonism">cinchonism</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, vasodilation and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, hearing impairment, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and disturbance in color perception. More severe symptoms of <span class="product-label-link" type="condition" conceptid="4292266" conceptname="Cinchonism">cinchonism</span> are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, and disturbances in cardiac rhythm or conduction. Most symptoms of <span class="product-label-link" type="condition" conceptid="4292266" conceptname="Cinchonism">cinchonism</span> are reversible and resolve with discontinuation of quinine.</p>
<p>The following ADVERSE REACTIONS have been reported with quinine sulfate. Most of these reactions are thought to be uncommon, but the actual incidence is unknown:</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, lupus-like syndrome, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>; <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, <span class="product-label-link" type="condition" conceptid="437216" conceptname="Black water fever">blackwater fever</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="4078700" conceptname="Lupus anticoagulant disorder">lupus anticoagulant</span>.</p>
<p><span class="Bold">Neuropsychiatric:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, altered mental status, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p><span class="Bold">Dermatologic:</span> cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, including urticarial, papular, or scarlatinal <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, acral <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, irregular rhythm, unifocal <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span>, nodal escape beats, U waves, QT prolongation, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, and <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Bold">Hepatobiliary:</span> granulomatous <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>.</p>
<p><span class="Bold">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</p>
<p><span class="Bold">Renal:</span> <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, including <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> with scotomata, sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">night blindness</span>, diminished visual fields, fixed pupillary dilatation, disturbed color vision, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, hearing impairment, and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7      DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1   Effects of Drugs and Other Substances on Quinine Pharmacokinetics</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Quinine is a P-gp substrate and is primarily metabolized by CYP3A4. Other enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 may contribute to the metabolism of quinine [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Bold">Antacids:</span> Antacids containing aluminum and/or magnesium may delay or decrease absorption of quinine. Concomitant administration of these antacids with QUALAQUIN should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Bold">Antiepileptics (AEDs) (carbamazepine, phenobarbital, and phenytoin):</span> Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with QUALAQUIN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<p class="First"><span class="Bold">Cholestyramine:</span> In 8 healthy subjects who received quinine sulfate 600 mg with or without 8 grams of cholestyramine resin, no significant difference in quinine pharmacokinetic parameters was seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.4"></a><p></p>
<p class="First"><span class="Bold">Cigarette Smoking (CYP1A2 inducer):</span> In healthy male heavy smokers, the mean quinine AUC following a single 600 mg dose was 44% lower, the mean C<span class="Sub">max</span> was 18% lower, and the elimination half-life was shorter (7.5 hours versus 12 hours) than in their non-smoking counterparts. However, in <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> patients who received the full 7-day course of quinine therapy, cigarette smoking produced only a 25% decrease in median quinine AUC and a 16.5% decrease in median C<span class="Sub">max</span>, suggesting that the already reduced clearance of quinine in acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> could have diminished the metabolic induction effect of smoking. Because smoking did not appear to influence the therapeutic outcome in <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> patients, it is not necessary to increase the dose of quinine in the treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in heavy cigarette smokers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.5"></a><p></p>
<p class="First"><span class="Bold">Grapefruit juice (P-gp/CYP3A4 inhibitor):</span> In a pharmacokinetic study involving 10 healthy subjects, the administration of a single 600 mg dose of quinine sulfate with grapefruit juice (full-strength or half-strength) did not significantly alter the pharmacokinetic parameters of quinine. QUALAQUIN may be taken with grapefruit juice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.6"></a><p></p>
<p class="First"><span class="Bold">Histamine H<span class="Sub">2</span>-receptor blockers [cimetidine, ranitidine (nonspecific CYP450 inhibitors)]:</span> In healthy subjects who were given a single oral 600 mg dose of quinine sulfate after pretreatment with cimetidine (200 mg three times daily and 400 mg at bedtime for 7 days) or ranitidine (150 mg twice daily for 7 days), the apparent oral clearance of quinine decreased and the mean elimination half-life increased significantly when given with cimetidine but not with ranitidine. Compared to untreated controls, the mean AUC of quinine increased by 20% with ranitidine and by 42% with cimetidine (p&lt;0.05) without a significant change in mean quinine C<span class="Sub">max</span>. When quinine is to be given concomitantly with a histamine H<span class="Sub">2</span>-receptor blocker, the use of ranitidine is preferred over cimetidine. Although cimetidine and ranitidine may be used concomitantly with QUALAQUIN, patients should be monitored closely for adverse events associated with quinine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.7"></a><p></p>
<p class="First"><span class="Bold">Isoniazid:</span> Isoniazid 300 mg/day pretreatment for 1 week did not significantly alter the pharmacokinetic parameter values of quinine. Adjustment of QUALAQUIN dosage is not necessary when isoniazid is given concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.8"></a><p></p>
<p class="First"><span class="Bold">Ketoconazole (CYP3A4 inhibitor):</span> In a crossover study, healthy subjects (N=9) who received a single oral dose of quinine hydrochloride (500 mg) concomitantly with ketoconazole (100 mg twice daily for 3 days) had a mean quinine AUC that was higher by 45% and a mean oral clearance of quinine that was 31% lower than after receiving quinine alone. Although no change in the QUALAQUIN dosage regimen is necessary with concomitant ketoconazole, patients should be monitored closely for adverse reactions associated with quinine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.9"></a><p></p>
<p class="First"><span class="Bold">Macrolide antibiotics (erythromycin, troleandomycin) (CYP3A4 inhibitors):</span> In a crossover study (N=10), healthy subjects who received a single oral 600 mg dose of quinine sulfate with the macrolide antibiotic, troleandomycin (500 mg every 8 hours) exhibited a 87% higher mean quinine AUC, a 45% lower mean oral clearance of quinine, and a 81% lower formation clearance of the main metabolite, 3-hydroxyquinine, than when quinine was given alone. Therefore, concomitant administration of troleandomycin with QUALAQUIN should be avoided.</p>
<p>Erythromycin was shown to inhibit the metabolism of quinine <span class="Italics">in vitro</span> using human liver microsomes. Therefore, concomitant administration of erythromycin with QUALAQUIN is likely to increase plasma quinine concentrations, and should be avoided [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.10"></a><p></p>
<p class="First"><span class="Bold">Oral contraceptives (estrogen, progestin): </span>In 7 healthy females who were using single-ingredient progestin or combination estrogen-containing oral contraceptives, the pharmacokinetic parameters of a single 600 mg dose of quinine sulfate were not altered in comparison to those observed in 7 age-matched female control subjects not using oral contraceptives.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.11"></a><p></p>
<p class="First"><span class="Bold">Rifampin (CYP3A4 inducer):</span> In patients with uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> who received quinine sulfate 10 mg/kg concomitantly with rifampin 15 mg/kg/day for 7 days (N=29), the median AUC of quinine between days 3 and 7 of therapy was 75% lower as compared to those who received quinine monotherapy. In healthy subjects (N=9) who received a single oral 600 mg dose of quinine sulfate after 2 weeks of pretreatment with rifampin 600 mg/day, the mean quinine AUC and C<span class="Sub">max</span> decreased by 85% and 55%, respectively. Therefore the concomitant administration of rifampin with QUALAQUIN should be avoided [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.12"></a><p></p>
<p class="First"><span class="Bold">Tetracycline:</span> In 8 patients with acute uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> who were treated with oral quinine sulfate (600 mg every 8 hours for 7 days) in combination with oral tetracycline (250 mg every 6 hours for 7 days), the mean plasma quinine concentrations were about two-fold higher than in 8 patients who received quinine monotherapy. Although tetracycline may be concomitantly administered with QUALAQUIN, patients should be monitored closely for adverse reactions associated with quinine sulfate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.13"></a><p></p>
<p class="First"><span class="Bold">Theophylline or aminophylline:</span> In 20 healthy subjects who received multiple doses of QUALAQUIN (648 mg every 8 hours × 7 days) with a single 300 mg oral dose of theophylline, the quinine mean C<span class="Sub">max</span> and AUC were increased by 13% and 14% respectively. Although no change in the QUALAQUIN dosage regimen is necessary with concomitant theophylline or aminophylline, patients should be monitored closely for adverse reactions associated with quinine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.14"></a><p></p>
<p class="First"><span class="Bold">Urinary alkalizers (acetazolamide, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>):</span> Urinary alkalinizing agents may increase plasma quinine concentrations.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2     Effects of Quinine on the Pharmacokinetics of Other Drugs</h2>
<p class="First">Results of <span class="Italics">in vivo</span> drug interaction studies suggest that quinine has the potential to inhibit the metabolism of drugs that are substrates of CYP3A4 and CYP2D6. Quinine inhibits P-gp and has the potential to affect the transport of drugs that are P-gp substrates. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Bold">Anticonvulsants (carbamazepine, phenobarbital, and phenytoin):</span>  A single 600 mg oral dose of quinine sulfate increased the mean plasma C<span class="Sub">max</span>, and AUC<span class="Sub">0–24</span> of single oral doses of carbamazepine (200 mg) and phenobarbital (120 mg) but not phenytoin (200 mg) in 8 healthy subjects. The mean AUC increases of carbamazepine, phenobarbital and phenytoin were 104%, 81% and 4%, respectively; the mean increases in C<span class="Sub">max</span> were 56%, 53%, and 4%, respectively. Mean urinary recoveries of the three antiepileptics over 24 hours were also profoundly increased by quinine. If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. Additionally, patients should be monitored closely for adverse reactions associated with these anticonvulsants. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Bold">Astemizole (CYP3A4 substrate):</span>  Elevated plasma astemizole concentrations were reported in a subject who experienced <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> after receiving three doses of quinine sulfate for nocturnal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> concomitantly with chronic astemizole 10 mg/day. The concurrent use of QUALAQUIN with astemizole and other CYP3A4 substrates with QT prolongation potential (e.g., <span class="Bold">cisapride, terfenadine, halofantrine, pimozide and quinidine</span>) should also be avoided [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<p class="First"><span class="Bold">Atorvastatin (CYP3A4 substrate):</span> <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> was reported in a patient taking atorvastatin administered with a single dose of quinine. Quinine may increase plasma concentrations of atorvastatin, thereby increasing the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Thus, clinicians considering combined therapy of QUALAQUIN with atorvastatin or other HMG-CoA reductase inhibitors ("statins") that are CYP3A4 substrates (e.g., simvastatin, lovastatin) should carefully weigh the potential benefits and risks of each medication. If QUALAQUIN is used concomitantly with any of these statins, lower starting and maintenance doses of the statin should be considered. Patients should also be monitored closely for any signs or symptoms of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly during initial therapy. If marked creatine phosphokinase (CPK) elevation occurs or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (defined as <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with CPK values &gt;10 times the upper limit of normal) is diagnosed or suspected, atorvastatin or other statin should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.4"></a><p></p>
<p class="First"><span class="Bold">Desipramine (CYP2D6 substrate):</span> Quinine (750 mg/day for 2 days) decreased the metabolism of desipramine in patients who were extensive CYP2D6 metabolizers, but had no effect in patients who were poor CYP2D6 metabolizers. Lower doses (80 mg to 400 mg) of quinine did not significantly affect the pharmacokinetics of other CYP2D6 substrates, namely, debrisoquine, dextromethorphan, and methoxyphenamine. Although clinical drug interaction studies have not been performed, antimalarial doses (greater than or equal to 600 mg) of quinine may inhibit the metabolism of other drugs that are CYP2D6 substrates (e.g., <span class="Bold">flecainide, debrisoquine, dextromethorphan, metoprolol, paroxetine</span>). Patients taking medications that are CYP2D6 substrates with QUALAQUIN should be monitored closely for adverse reactions associated with these medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.5"></a><p></p>
<p class="First"><span class="Bold">Digoxin (P-gp substrate):</span> In 4 healthy subjects who received digoxin (0.5 to 0.75 mg/day) during treatment with quinine (750 mg/day), a 33% increase in mean steady state AUC of digoxin and a 35% reduction in the steady-state biliary clearance of digoxin were observed compared to digoxin alone. Thus, if QUALAQUIN is administered to patients receiving digoxin, plasma digoxin concentrations should be closely monitored, and the digoxin dose adjusted, as necessary [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.6"></a><p></p>
<p class="First"><span class="Bold">Halofantrine:</span> Although not studied clinically, quinine was shown to inhibit the metabolism of halofantrine <span class="Italics">in vitro</span> using human liver microsomes. Therefore, concomitant administration of QUALAQUIN is likely to increase plasma halofantrine concentrations [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.7"></a><p></p>
<p class="First"><span class="Bold">Mefloquine:</span> In 7 healthy subjects who received mefloquine (750 mg) at 24 hours before an oral 600 mg dose of quinine sulfate, the AUC of mefloquine was increased by 22% compared to mefloquine alone. In this study, the QTc interval was significantly prolonged in the subjects who received mefloquine and quinine sulfate 24 hours apart. The concomitant administration of mefloquine and QUALAQUIN may produce electrocardiographic abnormalities (including QTc prolongation) and may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.8"></a><p></p>
<p class="First"><span class="Bold">Midazolam (CYP3A4 substrate):</span> In 23 healthy subjects who received multiple doses of QUALAQUIN 324 mg three times daily × 7 days with a single oral 2 mg dose of midazolam, the mean AUC and C<span class="Sub">max</span> of midazolam and 1-hydroxymidazolam were not significantly affected. This finding indicates that 7-day dosing with QUALAQUIN 324 mg every 8 hours did not induce the metabolism of midazolam.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.9"></a><p></p>
<p class="First"><span class="Bold">Neuromuscular blocking agents (pancuronium, succinylcholine, tubocurarine):</span> In one report, quinine potentiated <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> in a patient who received pancuronium during an operative procedure, and subsequently (3 hours after receiving pancuronium) received quinine 1800 mg daily. Quinine may also enhance the neuromuscular blocking effects of succinylcholine and tubocurarine [<span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.10"></a><p></p>
<p class="First"><span class="Bold">Theophylline or aminophylline (CYP1A2 substrate):</span> In 19 healthy subjects who received multiple doses of QUALAQUIN 648 mg every 8 hours × 7 days with a single 300 mg oral dose of theophylline, the mean theophylline AUC was 10% lower than when theophylline was given alone. There was no significant effect on mean theophylline C<span class="Sub">max</span>. Therefore, if QUALAQUIN is co-administered to patients receiving theophylline or aminophylline, plasma theophylline concentrations should be monitored frequently to ensure therapeutic concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.11"></a><p></p>
<p class="First"><span class="Bold">Warfarin and oral anticoagulants:</span> Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. Quinine may also interfere with the anticoagulant effect of heparin. Thus, in patients receiving these anticoagulants, the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), partial thromboplastin time (PTT), or international normalization ratio (INR) should be closely monitored as appropriate, during concurrent therapy with QUALAQUIN.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3     Drug/Laboratory Interactions</h2>
<p class="First">Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8       USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<p>There are extensive published data but few well-controlled studies of QUALAQUIN in pregnant women. Published data on over 1,000 pregnancy exposures to quinine did not show an increase in teratogenic effects over the background rate in the general population; however the majority of these exposures were not in the first trimester. In developmental and reproductive toxicity studies, central nervous system (CNS) and ear abnormalities and increased <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> occurred in some species when pregnant animals received quinine at doses about 1 to 4 times the human clinical dose. Quinine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p><span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> carries a higher risk of morbidity and mortality in pregnant women than in the general population. Pregnant women with <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> have an increased incidence of fetal loss (including <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span>), preterm labor and delivery, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, low birth weight, and maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Therefore, treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in pregnancy is important.</p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>, due to increased pancreatic secretion of insulin, has been associated with quinine use, particularly in pregnant women.</p>
<p>Quinine crosses the placenta with measurable blood concentrations in the fetus. In 8 women who delivered live infants 1 to 6 days after starting quinine therapy, umbilical cord plasma quinine concentrations were between 1.0 and 4.6 mg/L (mean 2.4 mg/L) and the mean (±SD) ratio of cord plasma to maternal plasma quinine concentrations was 0.32 ± 0.14. Quinine levels in the fetus may not be therapeutic. If congenital <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> is suspected after delivery, the infant should be evaluated and treated appropriately.</p>
<p>A study from Thailand (1999) of women with <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> who were treated with oral quinine sulfate 10 mg/kg 3 times daily for 7 days at anytime in pregnancy reported no significant difference in the rate of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> at &gt;28 weeks of gestation in women treated with quinine (10 of 633 women [1.6%]) as compared with a control group without <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or exposure to antimalarial drugs during pregnancy (40 of 2201 women [1.8%]). The overall rate of congenital malformations (9 of 633 offspring [1.4%]) was not different for women who were treated with quinine sulfate compared with the control group (38 of 2201 offspring [1.7%]). The <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> rate was higher in the control group (10.9%) than in women treated with quinine sulfate (3.5%) [OR = 3.1; 95% CI 2.1-4.7]. An epidemiologic survey that included 104 mother-child pairs exposed to quinine during the first 4 months of pregnancy, found no increased risk of structural <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> was seen (2 <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> [1.9%]). Rare and isolated case reports describe <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> and optic nerve hypoplasia in children exposed <span class="Italics">in utero</span> due to maternal ingestion of high doses of quinine.</p>
<p>In animal developmental studies conducted in multiple animal species, pregnant animals received quinine by the subcutaneous or intramuscular route at dose levels similar to the maximum recommended human dose (based on body surface area). In rabbits, chinchillas, and dogs, there were increases in <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> <span class="Italics">in utero</span>. Rabbit offspring had increased rates of degenerated auditory nerve and spiral <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span>; chinchilla offspring had increased rates of growth restriction <span class="Italics">in utero</span>; and both rabbit and chinchilla offspring had increased rates of  CNS anomalies such as <span class="product-label-link" type="condition" conceptid="377368" conceptname="Anencephalus">anencephaly</span> and <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>. Guinea pig offspring had increased rates of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and mitochondrial change in the cochlea. There were no teratogenic findings in rats and monkeys.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2     Labor and Delivery</h2>
<p class="First">There is no evidence that quinine causes uterine contractions at the doses recommended for the treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. In doses several-times higher than those used to treat <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, quinine may stimulate the pregnant uterus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3     Nursing Mothers</h2>
<p class="First">There is limited information on the safety of quinine in breastfed infants. No toxicity was reported in infants in a single study where oral quinine sulfate (10 mg/kg every 8 hours for 1 to 10 days) was administered to 25 lactating women. It is estimated from this study that breastfed infants would receive less than 2 to 3 mg per day of quinine base (&lt; 0.4% of the maternal dose) <span class="Italics">via</span> breast milk [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Although quinine is generally considered compatible with breastfeeding, the risks and benefits to infant and mother should be assessed. Caution should be exercised when administered to a nursing woman. </p>
<p>If <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> is suspected in the infant, appropriate evaluation and treatment should be provided. Plasma quinine levels may not be therapeutic in infants of nursing mothers receiving QUALAQUIN.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4     Pediatric Use</h2>
<p class="First">The safety and efficacy of QUALAQUIN in pediatric patients under the age of 16 has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5     Geriatric Use</h2>
<p class="First">Clinical studies of quinine sulfate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6     <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Clearance of quinine is decreased in patients with severe <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>. The dosage and dosing frequency should be reduced [<span class="Italics">see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Close monitoring is recommended for patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>, as it may increase exposure to quinine [<span class="Italics">see <a href="#S12.3">Clinical  Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10      OVERDOSAGE</h1>
<p class="First">Quinine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> can be associated with serious complications, including <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Visual impairment</span> can range from <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and defective color perception, to <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field constriction</span> and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>. <span class="product-label-link" type="condition" conceptid="4292266" conceptname="Cinchonism">Cinchonism</span> occurs in virtually all patients with quinine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Symptoms range from <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, hearing impairment, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, to <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. Central nervous system toxicity (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, disturbances of consciousness, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>) has also been reported with quinine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, as well as <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>.</p>
<p>Most toxic reactions are dose-related; however, some reactions may be idiosyncratic because of the variable sensitivity of patients to the toxic effects of quinine. A lethal dose of quinine has not been clearly defined, but fatalities have been reported after the ingestion of 2 to 8 grams in adults.</p>
<p>Quinine, like quinidine, has Class I antiarrhythmic properties. The cardiotoxicity of quinine is due to its negative inotropic action, and to its effect on cardiac conduction, resulting in decreased rates of depolarization and conduction, and increased action potential and effective refractory period. ECG changes observed with quinine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, PR prolongation, T wave inversion, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, an increased QT interval, and a widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span>. Quinine's alpha-blocking properties may result in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and further exacerbate myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> by decreasing coronary perfusion. Quinine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been also associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, idioventricular rhythm, and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, as well as <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> [<span class="Italics">see <a href="#S5">Warnings and Precautions (5)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Quinine is rapidly absorbed, and attempts to remove residual quinine sulfate from the stomach by gastric lavage may not be effective. Multiple-dose activated charcoal has been shown to decrease plasma quinine concentrations [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Forced acid <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, hemodialysis, charcoal column hemoperfusion, and plasma exchange were not found to be effective in significantly increasing quinine elimination in a series of 16 patients.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11      DESCRIPTION</h1>
<p class="First">QUALAQUIN (quinine sulfate) is a cinchona alkaloid chemically described as cinchonan-9-ol, 6'-methoxy-, (8α, 9R)-, sulfate (2:1) (salt), dihydrate with a molecular formula of (C<span class="Sub">20</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">2</span>)<span class="Sub">2</span>•H<span class="Sub">2</span>SO<span class="Sub">4</span>•2H<span class="Sub">2</span>O and a molecular weight of 782.96. </p>
<p>The structural formula of quinine sulfate is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce2ffee3-3048-43a0-ac45-ee32ce0c4c33&amp;name=qualaquin-01.jpg"></div>
<p>Quinine sulfate occurs as a white, crystalline powder that darkens on exposure to light. It is odorless and has a persistent very bitter taste. It is only slightly soluble in water, alcohol, chloroform, and ether. </p>
<p>QUALAQUIN is supplied for oral administration as capsules containing 324 mg of the active ingredient quinine sulfate USP, equivalent to 269 mg free base. Inactive ingredients: corn starch, magnesium stearate, and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12      CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1   Mechanism of Action</h2>
<p class="First">Quinine is an antimalarial agent [<span class="Italics">see <a href="#S12.4">Clinical Pharmacology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2   Pharmacodynamics</h2>
<p class="First">QTc interval prolongation was evaluated in a crossover pharmacokinetic study in healthy subjects (N=24) who received single oral doses of QUALAQUIN (324 mg and 648 mg). The mean ± SD maximum QTc change from baseline around the quinine T<span class="Sub">max</span> was 10 ± 19 msec and 12 ± 18 msec, respectively for the 324 mg and 648 mg doses. There were no subjects who had a QTc interval greater than 500 msec, or had a maximum QTc change from baseline of greater than 60 msec [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3   Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics Underline">Absorption</span></p>
<p>The oral bioavailability of quinine is 76 to 88% in healthy adults. Quinine exposure is higher in patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> than in healthy subjects. After a single oral dose of quinine sulfate, the mean quinine T<span class="Sub">max </span>was longer, and mean AUC and C<span class="Sub">max</span> were higher in patients with uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> than in healthy subjects, as shown in Table 1 below.</p>
<a name="table1"></a><table width="80%">
<caption><span>TABLE 1 Pharmacokinetic Parameters of Quinine in Healthy Subjects and Patients with Uncomplicated P. <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum Malaria</span> after a Single Dose<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> of Oral Quinine Sulfate Capsules</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Healthy Subjects<br>(N = 23)<br>Mean ± SD</th>
<th class="Rrule" align="center">Uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> Patients<br>(N = 15)<br>Mean ± SD</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Quinine Sulfate dose was 648 mg (approximately 8.7 mg/kg) in healthy subjects; and 10 mg/kg in patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Dose (mg/kg)<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">8.7</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">T<span class="Sub">max</span> (h)</td>
<td class="Rrule" align="center">2.8 ± 0.8</td>
<td class="Rrule" align="center">5.9 ± 4.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (mcg/mL)</td>
<td class="Rrule" align="center">3.2 ± 0.7</td>
<td class="Rrule" align="center">8.4</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0–12 </span>(mcg*h/mL)</td>
<td class="Rrule" align="center">28.0</td>
<td class="Rrule" align="center">73.0</td>
</tr>
</tbody>
</table>
<p>QUALAQUIN capsules may be administered without regard to meals. When a single oral 324 mg capsule of QUALAQUIN was administered to healthy subjects (N=26) with a standardized high-fat breakfast, the mean T<span class="Sub">max</span> of quinine was prolonged to about 4.0 hours, but the mean C<span class="Sub">max</span> and AUC<span class="Sub">0-24h </span>were similar to those achieved when QUALAQUIN capsule was given under fasted conditions [<span class="Italics">see <a href="#S2.1">Dosage and Administration (2.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics Underline">Distribution</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, the volume of distribution (Vd/F) decreases in proportion to the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. In published studies with healthy subjects who received a single oral 600 mg dose of quinine sulfate, the mean Vd/F ranged from 2.5 to 7.1 L/kg.</p>
<p>Quinine is moderately protein-bound in blood in healthy subjects, ranging from 69 to 92%. During active malarial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, protein binding of quinine is increased to 78 to 95%, corresponding to the increase in α<span class="Sub">1</span>-acid glycoprotein that occurs with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Intra-erythrocytic levels of quinine are approximately 30 to 50% of the plasma concentration.</p>
<p>Quinine penetrates relatively poorly into the cerebrospinal fluid (CSF) in patients with <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>, with CSF concentration approximately 2 to 7% of plasma concentration.</p>
<p>In one study, quinine concentrations in placental cord blood and breast milk were approximately 32% and 31%, respectively, of quinine concentrations in maternal plasma. The estimated total dose of quinine secreted into breast milk was less than 2 to 3 mg per day [<span class="Italics">see <a href="#S8.1">Use in Specific Populations (8.1</a>, <a href="#S8.3">8.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics Underline">Metabolism</span></p>
<p>Quinine is metabolized almost exclusively <span class="Italics">via</span> hepatic oxidative cytochrome P450 (CYP) pathways, resulting in four primary metabolites, 3-hydroxyquinine, 2´-quinone, <span class="Italics">O</span>-desmethylquinine, and 10,11-dihydroxydihydroquinine. Six secondary metabolites result from further biotransformation of the primary metabolites. The major metabolite, 3-hydroxyquinine, is less active than the parent drug. <span class="Italics">In vitro </span>studies using human liver microsomes and recombinant P450 enzymes have shown that quinine is metabolized mainly by CYP3A4. Depending on the<span class="Italics"> in vitro</span> experimental conditions, other enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were shown to have some role in the metabolism of quinine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Elimination/Excretion</span></span></p>
<p>Quinine is eliminated primarily <span class="Italics">via</span> hepatic biotransformation. Approximately 20% of quinine is excreted unchanged in urine. Because quinine is reabsorbed when the urine is alkaline, renal excretion of the drug is twice as rapid when the urine is acidic than when it is alkaline.</p>
<p>In various published studies, healthy subjects who received a single oral 600 mg dose of quinine sulfate exhibited a mean plasma clearance ranging from 0.08 to 0.47 L/h/kg (median value: 0.17 L/h/kg) with a mean plasma elimination half-life of 9.7 to 12.5 hours.</p>
<p>In 15 patients with uncomplicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> who received a 10 mg/kg oral dose of quinine sulfate, the mean total clearance of quinine was slower (approximately 0.09 L/h/kg) during the acute phase of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and faster (approximately 0.16 L/h/kg) during the recovery or convalescent phase.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Bold">Extracorporeal Elimination:</span> Administration of multiple-dose activated charcoal (50 grams administered 4 hours after quinine dosing followed by 3 further doses over the next 12 hours) decreased the mean quinine elimination half-life from 8.2 to 4.6 hours, and increased the mean quinine clearance by 56% (from 11.8 L/h to 18.4 L/h) in 7 healthy adult subjects who received a single oral 600 mg dose of quinine sulfate. Likewise, in 5 symptomatic patients with acute quinine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> who received multiple-dose activated charcoal (50 grams every 4 hours), the mean quinine elimination half-life was shortened to 8.1 hours in comparison to a half-life of approximately 26 hours in patients who did not receive activated charcoal [<span class="Italics">see <a href="#S10">Overdosage (10)</a></span>].</p>
<p>In 6 patients with quinine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, forced acid <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> did not change the half-life of quinine elimination (25.1 ± 4.6 hours <span class="Italics">vs.</span> 26.5 ± 5.8 hours), or the amount of unchanged quinine recovered in the urine, in comparison to 8 patients not treated in this manner [<span class="Italics">see <a href="#S10">Overdosage (10)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Underline">Pediatric Patients</span>: The pharmacokinetics of quinine in children (1.5 to 12 years old) with uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> appear to be similar to that seen in adults with uncomplicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Furthermore, as seen in adults, the mean total clearance and the volume of distribution of quinine were reduced in pediatric patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> as compared to the healthy pediatric controls. Table 2 below provides a comparison of the mean ± SD pharmacokinetic parameters of quinine in pediatric patients <span class="Italics">vs.</span> healthy pediatric controls.</p>
<a name="table2"></a><table width="80%">
<caption><span>TABLE 2 Quinine Pharmacokinetic Parameters Following the First 10 mg/kg Quinine Sulfate Oral Dose in Healthy Pediatric Controls and Pediatric Patients with Acute Uncomplicated P. <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum Malaria</span></span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Healthy Pediatric Controls<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a><br>(N = 5)<br>Mean ± SD</th>
<th class="Rrule" align="center">
<span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> Pediatric Patients<span class="Sup">1</span><br>(N = 15)<br>Mean ± SD</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>age 1.5 to 12 years</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">T<span class="Sub">max</span> (h)</td>
<td class="Rrule" align="center">2.0</td>
<td class="Rrule" align="center">4.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (mcg/mL)</td>
<td class="Rrule" align="center">3.4 ± 1.18</td>
<td class="Rrule" align="center">7.5 ± 1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Half-life (h)</td>
<td class="Rrule" align="center">3.2 ± 0.3</td>
<td class="Rrule" align="center">12.1 ± 1.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total CL (L/h/kg)</td>
<td class="Rrule" align="center">0.30 ± 0.04</td>
<td class="Rrule" align="center">0.06 ± 0.01</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Vd (L/kg)</td>
<td class="Rrule" align="center">1.43 ± 0.18</td>
<td class="Rrule" align="center">0.87 ± 0.12</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Underline">Geriatric Patients:</span> Following a single oral dose of 600 mg quinine sulfate, the mean AUC was about 38% higher in 8 healthy elderly subjects (65 to 78 years old) than in 12 younger subjects (20 to 35 years old). The mean T<span class="Sub">max</span> and C<span class="Sub">max</span> were similar in elderly and younger subjects after a single oral dose of quinine sulfate 600 mg. The mean oral clearance of quinine was significantly decreased, and the mean elimination half-life was significantly increased in elderly subjects compared with younger subjects (0.06 <span class="Italics">vs.</span> 0.08 L/h/kg, and 18.4 hours <span class="Italics">vs.</span> 10.5 hours, respectively). Although there was no significant difference in the renal clearance of quinine between the two age groups, elderly subjects excreted a larger proportion of the dose in urine as unchanged drug than younger subjects (16.6% <span class="Italics">vs.</span> 11.2%). Although an alteration in the QUALAQUIN dosage regimen is not needed, elderly patients should be closely monitored for adverse reactions associated with quinine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Following a single oral 600 mg dose of quinine sulfate in otherwise healthy subjects with severe <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> not receiving any form of dialysis (mean serum creatinine = 9.6 mg/dL), the median AUC was higher by 195% and the median C<span class="Sub">max</span> was higher by 79% than in subjects with normal renal function (mean serum creatinine = 1 mg/dL). The mean plasma half-life in subjects with severe <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> was prolonged to 26 hours compared to 9.7 hours in the healthy controls. Computer assisted modeling and simulation indicates that in patients with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> and severe <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, a dosage regimen consisting of one loading dose of 648 mg QUALAQUIN followed 12 hours later by a maintenance dosing regimen of 324 mg every 12 hours will provide adequate systemic exposure to quinine [<span class="Italics">see <a href="#S2.2">Dosage and Administration (2.2)</a></span>]. The effects of mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics and safety of quinine sulfate are not known. </p>
<p>Negligible to minimal amounts of circulating quinine in the blood are removed by hemodialysis or hemofiltration. In subjects with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> (CRF) on hemodialysis, only about 6.5% of quinine is removed in 1 hour. Plasma quinine concentrations do not change during or shortly after hemofiltration in subjects with CRF [<span class="Italics">see <a href="#S10">Overdosage (10)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> In otherwise healthy subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B; N=9) who received a single oral 600 mg dose of quinine sulfate, the mean AUC increased by 55% without a significant change in mean C<span class="Sub">max</span>, as compared to healthy volunteer controls (N=6). In subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, the absorption of quinine was prolonged, the elimination half-life was increased, the apparent volume of distribution was higher, but there was no significant difference in weight-adjusted clearance. Therefore, in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, dosage adjustment is not needed, but patients should be monitored closely for adverse effects of quinine [<span class="Italics">see <a href="#S8.7">Use in Specific Populations (8.7)</a></span>]. No pharmacokinetic data are available for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.4"></a><p></p>
<h2>12.4   Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.1"></a><p></p>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Quinine inhibits nucleic acid synthesis, protein synthesis, and glycolysis in <span class="Italics">Plasmodium falciparum</span> and can bind with hemazoin in parasitized erythrocytes. However, the precise mechanism of the antimalarial activity of quinine sulfate is not completely understood.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.2"></a><p></p>
<p class="First"><span class="Bold">Activity <span class="Italics">In Vitro</span> and <span class="Italics">In Vivo</span></span></p>
<p>Quinine sulfate acts primarily on the blood schizont form of <span class="Italics">P. falciparum. </span>It is not gametocidal and has little effect on the sporozoite or pre-erythrocytic forms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> of <span class="Italics">P. falciparum</span> with decreased susceptibility to quinine can be selected <span class="Italics">in vivo</span>. <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> that is clinically resistant to quinine has been reported in some areas of South America, Southeast Asia, and Bangladesh.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13      NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Carcinogenicity studies of quinine have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis</span></p>
<p>Genotoxicity studies of quinine were positive in the Ames bacterial mutation assay with metabolic activation and in the sister chromatid exchange assay in mice. The sex-linked recessive lethal test performed in <span class="Italics">Drosophila</span>, the <span class="Italics">in vivo</span> mouse micronucleus assay, and the chromosomal aberration assay in mice and Chinese hamsters were negative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility</span></p>
<p>Studies to evaluate the effect of quinine upon fertility in animals or in humans have not been conducted. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14      CLINICAL STUDIES</h1>
<p class="First">Quinine has been used worldwide for hundreds of years in the treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Thorough searches of the published literature identified over 1300 references to the treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> with quinine, and from these, 21 randomized, active-controlled studies were identified which evaluated oral quinine monotherapy or combination therapy for treatment of uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Over 2900 patients from <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas were enrolled in these studies, and more than 1400 patients received oral quinine. The following conclusions were drawn from review of these studies:</p>
<p>In areas where multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> of <span class="Italics">P. falciparum</span> is increasing, such as Southeast Asia, cure rates with 7 days of oral quinine monotherapy were at least 80%; while cure rates for 7 days of oral quinine combined with an antimicrobial agent (tetracycline or clindamycin) were greater than 90%. In areas where multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> of the parasite was not as widespread, cure rates with 7 days of quinine monotherapy ranged from 86 to 100%. Cure was defined as initial clearing of parasitemia within 7 days without recrudescence by day 28 after treatment initiation. <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> that is clinically resistant to quinine has been reported in some areas of South America, Southeast Asia, and Bangladesh, and quinine may not be as effective in those areas.</p>
<p>Completion of a 7-day oral quinine treatment regimen may be limited by <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span>, and shorter courses (3 days) of quinine combination therapy have been used. However, the published data from randomized, controlled clinical trials for shorter regimens of oral quinine in conjunction with tetracycline, doxycycline, or clindamycin for treatment of uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> is limited, and these shorter course combination regimens may not be as effective as the longer regimens.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16       HOW SUPPLIED / STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1    How Supplied</h2>
<p class="First">QUALAQUIN capsules USP, 324 mg are available as clear/clear capsules imprinted AR 102:</p>
<a name="i3314266c-57ae-434d-8585-9147f9467830"></a><table width="50%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Bottles of 30</td>
<td align="left">NDC 13310-153-07</td>
</tr>
<tr>
<td align="left">Bottles of 100</td>
<td align="left">NDC 13310-153-01</td>
</tr>
<tr>
<td align="left">Bottles of 500</td>
<td align="left">NDC 13310-153-05</td>
</tr>
<tr class="Botrule Last">
<td align="left">Bottles of 1000</td>
<td align="left">NDC 13310-153-10</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2   Storage</h2>
<p class="First">Store at 20° to 25ºC (68° to 77°F).</p>
<p>[See USP Controlled Room Temperature]</p>
<p>Dispense in a tight container as defined in the USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17       PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See <a href="#S17.2">FDA-approved Medication Guide (17.2)</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1   Dosing Instructions</h2>
<p class="First">Patients should be instructed to:</p>
<ul>
<li>Take all of the medication as directed.</li>
<li>Take no more of the medication than the amount prescribed.</li>
<li>Take with food to minimize possible <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>.</li>
</ul>
<p>If a dose is missed, patients should also be instructed not to double the next dose. If more than 4 hours has elapsed since the missed dose, the patient should wait and take the next dose as previously scheduled.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2   FDA-Approved Medication Guide</h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">QUALAQUIN<span class="Sup">®</span><br>(kwol</span>-a-kwin)</p>
<p><span class="Bold">(Quinine Capsules, USP)</span></p>
<p>Read the Medication Guide that comes with QUALAQUIN<span class="Bold"><span class="Sup">® </span></span>before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about QUALAQUIN<span class="Bold"><span class="Sup">® </span></span>when you start taking it and at regular checkups. QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> is not approved for the treatment of night-time <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>.</p>
<p><span class="Bold">What is the most important information I should know about QUALAQUIN<span class="Sup">®</span>?</span></p>
<p><span class="Bold">QUALAQUIN<span class="Sup">®</span> used to treat or prevent <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span> may cause serious side effects or even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<ul>
<li>QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> may cause your blood cell (platelet) to drop causing serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems. In some cases, kidney injury can also occur.</li>
<li>QUALAQUIN<span class="Sup">®</span> may cause problems with the heart rhythm that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>QUALAQUIN<span class="Sup">®</span> may cause serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you have:</span></p>
<ul>
<li>easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleed</span></li>
<li><span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span> or stool</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> gums</li>
<li>appearance of unusual purple, brown or red spots on your skin (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> under your skin)</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>sever <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face</li>
<li>trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li>rapid heartbeat</li>
<li>irregular heart rhythm</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></li>
</ul>
<p>Taking QUALAQUIN<span class="Sup">®</span> with some other medicines can increase the chance of serious side effects. Tell your health care provider if you take any other medicines.</p>
<p>Certain medicines can cause the blood levels of QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> to be too high or too low in your body. <span class="Bold">It is important for you to tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.</span></p>
<p>QUALAQUIN<span class="Sup">®</span> and other medicines may affect each other causing serious side effects or even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Even medicines that you may take for a short period of time, such as antibiotics, can mix in your blood with QUALAQUIN<span class="Sup">®</span> and cause serious side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold">Do not start taking a new medicine without telling your healthcare provider or pharmacist.</span></p>
<p><span class="Bold">What is QUALAQUIN<span class="Sup">®</span>?</span></p>
<p>QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> is a prescription medication used to treat uncomplicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> caused by the parasite <span class="Italics">Plasmodium falciparum.</span></p>
<p>QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> is <span class="Underline">NOT</span> approved to:</p>
<ul>
<li>Prevent <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span></li>
<li>Treat severe or complicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span></li>
<li>Prevent or treat night-time <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span></li>
</ul>
<p>It is not known if QUALAQUIN<span class="Sup">®</span> is safe and works in children younger than 16 years old.</p>
<p><span class="Bold">Who should not take QUALAQUIN<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Do not take QUALAQUIN<span class="Sup">®</span> if you:</span></p>
<ul>
<li>Have certain heart rhythm problems (<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>) or abnormal electrocardiogram (ECG) (QT prolongation).</li>
<li>Have low levels of an enzyme called Glucose-6-phosphate dehydrogenase (G6PD).</li>
<li>Have an autoimmune disease (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>) that leads to <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</li>
<li>Have had <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to quinine, quinidine, or mefloquine (Lariam<span class="Sup">®</span>).</li>
<li>Have had serious side effects to quinine (QUALAQUIN<span class="Sup">®</span>), such as low platelets, which are necessary for your blood to clot.</li>
<li>Have an <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the nerve important for vision (<span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>).</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before starting QUALAQUIN<span class="Sup">®</span>?</span></p>
<p>Before you take QUALAQUIN<span class="Sup">®</span>, tell your doctor or health care provider if you:</p>
<ul>
<li>Have heart problems.</li>
<li>Have kidney problems.</li>
<li>Have liver problems.</li>
<li>Have any other medical condition.</li>
<li>Are pregnant or could be pregnant. Treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> is important because it can be a serious disease for a pregnant woman and her unborn baby. Your doctor can tell you more about the benefits and risks of taking this medication during pregnancy. Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) can be seen in pregnant women while taking QUALAQUIN<span class="Sup">®</span>. This can include <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. You and your doctor can decide if QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> is right for you.</li>
<li>Are breast-feeding. Small amounts of QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> can pass into the breast milk. You and your healthcare provider can decide if you should breastfeed while taking QUALAQUIN<span class="Bold"><span class="Sup">®</span></span>.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, including prescription medicines, vitamins and herbal supplements.</span> See "<a href="#important">What is the most important information I should know about QUALAQUIN</a><span class="Sup">®</span>?</p>
<p><span class="Bold">How should I take QUALAQUIN<span class="Sup">®</span>?</span></p>
<ul>
<li>Take QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> exactly as your healthcare provider tells you to take it.</li>
<li>You healthcare provider will tell you how many QUALAQUIN<span class="Sup">®</span> capsules to take and when to take them.</li>
<li>To lower the chance of <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span>, take this medication WITH FOOD.</li>
<li>Finish all the QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> that is prescribed even if you feel better. Do not stop taking the medication without talking to your healthcare provider.</li>
<li>Do not take more than the amount prescribed. Do not take more than 2 capsules at one time or more than 3 doses in one day. If you take more than the prescribed dose, call your healthcare provider right away. If you forget to take QUALAQUIN<span class="Sup">®</span>, do NOT double the next dose. If it has been more than 4 hours since the missed dose, just wait and take the regular dose at the next scheduled time. Call your healthcare provider if you are not sure what to do.</li>
<li>If you take too much QUALAQUIN<span class="Sup">®</span> call your healthcare provider or go to the nearest emergency room right away.</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if:</span></p>
<ul>
<li>If you feel worse, or if you do not start feeling better within 1 or 2 days of starting to take QUALAQUIN<span class="Sup">®</span>.</li>
<li>If your <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> comes back after finishing treatment with QUALAQUIN<span class="Sup">®</span>.</li>
</ul>
<p><span class="Bold">What are the possible side effects of QUALAQUIN<span class="Sup">®</span>?</span></p>
<p><span class="Bold">QUALAQUIN<span class="Sup">®</span> may cause serious side effects.</span></p>
<ul>
<li>See "<a href="#important">What is the most important information I should know about QUALAQUIN</a><span class="Sup">®</span>" section.</li>
<li>Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). This can include <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. If you experience symptoms of low blood sugar, drink some fruit juice or eat a snack, and call your healthcare provider.</li>
</ul>
<p>Common side effects with QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li>Ringing in your ears</li>
<li><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span></li>
<li>Change in how you see color</li>
</ul>
<p>Less common side effects with QUALAQUIN<span class="Sup">®</span> include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span></li>
<li><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of QUALAQUIN<span class="Bold"><span class="Sup">®</span></span>. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store QUALAQUIN<span class="Sup">®</span>?</span></p>
<ul>
<li>Keep the capsules in a tightly closed container.</li>
<li>Do not refrigerate or freeze.</li>
<li>Store at 20° to 25°C (68º to 77°F).</li>
</ul>
<p><span class="Bold">Keep QUALAQUIN<span class="Sup">®</span> out of reach of children.</span></p>
<p><span class="Bold">General Information about QUALAQUIN<span class="Sup">®</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> for a condition for which it was not prescribed. Do not give QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about QUALAQUIN<span class="Bold"><span class="Sup">®</span></span>. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about QUALAQUIN<span class="Bold"><span class="Sup">®</span></span> that is written for healthcare professionals.</p>
<p>For more information, go to www.QUALAQUIN.com or call 1-888-351-3786.</p>
<p><span class="Bold">What are the ingredients in QUALAQUIN<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Active Ingredients:</span> Quinine Sulfate, USP</p>
<p><span class="Bold">Inactive Ingredients:</span> Corn starch, magnesium stearate, talc</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Manufactured for:<br>AR SCIENTIFIC, INC.<br>Philadelphia, PA 19124  USA<br>by:<br>MUTUAL PHARMACEUTICAL COMPANY, INC.<br>Philadelphia, PA 19124  USA</p>
<p>Rev 11, December 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><img alt="QUALAQUIN 324MG LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce2ffee3-3048-43a0-ac45-ee32ce0c4c33&amp;name=QUALAQUIN%20324MG%20LABEL.jpg">     QUALAQUIN 324MG LABEL IMAGE</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>QUALAQUIN 		
					</strong><br><span class="contentTableReg">quinine sulfate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-595(NDC:13310-153)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>QUININE SULFATE</strong> (QUININE) </td>
<td class="formItem">QUININE SULFATE</td>
<td class="formItem">324 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (CLEAR) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AR;102</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-595-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-595-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-595-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021799</td>
<td class="formItem">08/12/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>48639180-e4a0-49b2-a348-0b4d3fc69151</div>
<div>Set id: ce2ffee3-3048-43a0-ac45-ee32ce0c4c33</div>
<div>Version: 1</div>
<div>Effective Time: 20100318</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
